Cambridge Investment Research Advisors’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-38,905
Closed -$619K 3837
2025
Q3
$619K Sell
38,905
-2,934
-7% -$48.3K ﹤0.01% 2470
2025
Q2
$741K Buy
+41,839
New +$815K ﹤0.01% 2191
2024
Q4
Sell
-29,277
Closed -$574K 3481
2024
Q3
$574K Buy
+29,277
New +$582K ﹤0.01% 2294
2024
Q1
Sell
-43,296
Closed -$734K 3317
2023
Q4
$734K Buy
43,296
+3,345
+8% +$66.5K ﹤0.01% 1871
2023
Q3
$793K Sell
39,951
-4,477
-10% -$84.8K ﹤0.01% 1724
2023
Q2
$833K Buy
44,428
+952
+2% +$19.2K ﹤0.01% 1734
2023
Q1
$887K Sell
43,476
-34,819
-44% -$700K ﹤0.01% 1651
2022
Q4
$1.66M Sell
78,295
-79,824
-50% -$1.65M 0.01% 1185
2022
Q3
$3.21M Buy
+158,119
New +$3.15M 0.02% 784
2020
Q4
Sell
-13,978
Closed -$330K 2718
2020
Q3
$330K Buy
+13,978
New +$335K ﹤0.01% 1872
2019
Q3
Sell
-10,179
Closed -$223K 2347
2019
Q2
$223K Buy
+10,179
New +$222K ﹤0.01% 1932
2019
Q1
Sell
-134,736
Closed -$2.98M 2287
2018
Q4
$2.98M Buy
+134,736
New +$2.87M 0.03% 494

Other funds holding BTAL

Cambridge Investment Research Advisors's BTAL Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2025, closing a stake of 38,905 shares — an estimated $619K sold.

Cambridge Investment Research Advisors first reported a position in BTAL in Q4 2018 and held it in 12 quarters. The position peaked at $3.21M in Q3 2022. 81 funds tracked by Wall St. Rank hold BTAL as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 38,905 AGF US Market Neutral Anti-Beta Fund shares in Q4 2025, an estimated $619K.
  • Cambridge Investment Research Advisors first reported a position in AGF US Market Neutral Anti-Beta Fund in Q4 2018 and held it in 12 quarters.
  • Cambridge Investment Research Advisors's AGF US Market Neutral Anti-Beta Fund position peaked at $3.21M in Q3 2022.
  • 81 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.